Genmab Reports Positive EPCORE FL-1 Data for Epcoritamab Combination
COPENHAGEN, Denmark, June 11, 2026 Genmab A/S announced new subgroup analysis results from the pivotal Phase 3 EPCORE FL-1...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
COPENHAGEN, Denmark, June 11, 2026 Genmab A/S announced new subgroup analysis results from the pivotal Phase 3 EPCORE FL-1...
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
Paris, France | May 28, 2026 Enterome announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to...
NORTH CHICAGO, IL – November 18, 2025 — AbbVie announced that the U.S. Food and Drug Administration (FDA) has...
Marlborough, MA – October 17, 2025 – Boston Scientific Corporation announced that it has entered into a definitive agreement...
Paris, France – October 16, 2025 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
